Clinical Trials

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT01774630 2026-05-26

NiloPost-STIM

31 enrolled

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04449549 2026-05-22

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

82 enrolled

Neoplasms

NCT05554341 2026-05-14

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

40 enrolled

Neoplasm Metastasis

NCT04877522 2026-05-11

Asciminib Roll-over Study

Phase 4 Recruiting

347 enrolled

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04626024 2026-05-04

TOKIN

17 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03784014 2026-04-29

MULTISARC

603 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma

NCT02379416 2026-04-21

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

47 enrolled

Neoplasms

NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

104 enrolled 33 charts

Phase 3 Active not recruiting

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

405 enrolled 18 charts 1 FDA

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03516279 2026-04-03

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

40 enrolled

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT03874858 2026-04-02

DANTE

124 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01207492 2026-02-20

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

17 enrolled 8 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT04903119 2026-02-13

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Phase 1 Recruiting

30 enrolled

Dermatologic

Melanoma

NCT00756509 2026-01-20

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

Phase 4 Completed

34 enrolled 11 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01407198 2025-12-19

Nilotinib With Radiation for High Risk Chordoma

23 enrolled

Sarcoma

Chordoma

NCT03654768 2025-12-18

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

81 enrolled 20 charts

Leukemia, Myeloid, Chronic-Phase

NCT01316250 2025-10-02

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Phase NA Completed

13 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02201459 2025-10-02

PETALs

200 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02917720 2025-09-22

NAUT

75 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01784068 2025-09-10

ENESTfreedom

215 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01698905 2025-09-02

ENESTop

163 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07138378 2025-08-22

XS003-11

128 enrolled

Neoplasms

NCT02029001 2025-08-07

MOST plus

900 enrolled

Neoplasm Metastasis

NCT04838041 2025-07-30

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

51 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT06409936 2025-07-08

PEARL

160 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04205903 2025-06-29

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

11 enrolled 9 charts

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1 Terminated

8 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT01804985 2025-03-14

DESTINY

174 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03906292 2025-03-10

CMLXI

125 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05185947 2025-03-07

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

GastrointestinalGynecologic

19 enrolled

Appendiceal Neoplasms, Genital Neoplasms, Female, Necrosis, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms

NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

144 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04147533 2024-11-26

HALF

150 enrolled

Substance Withdrawal Syndrome, Leukemia, Myeloid, Chronic-Phase

NCT01863745 2024-08-19

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

15 enrolled 7 charts

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT02326311 2024-08-13

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

229 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02001818 2024-08-06

PInNACLe

60 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02081378 2024-03-18

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

326 enrolled 1 FDA

GastrointestinalLymphoidMyeloidOther hematologic neoplasmSarcoma

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01735955 2024-02-08

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Phase 4 Completed

57 enrolled 8 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Piebaldism, Gastrointestinal Stromal Tumors, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Neoplasms

NCT01657604 2023-05-10

TIGER

717 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02269267 2023-03-03

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

173 enrolled 14 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02546674 2022-07-22

NILOdeepR

Phase 4 Completed

171 enrolled 23 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04006847 2022-07-01

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Phase 1/2 Terminated

1 enrolled 5 charts

Leukemia, Myeloid, Chronic-Phase

NCT02353728 2022-03-25

Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

16 enrolled 7 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04835584 2022-03-21

KRT-232 and TKI Study in Chronic Myeloid Leukemia

Phase 1/2 Recruiting

109 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03942094 2022-03-16

Nilotinib for First-line Newly Diagnosed CML-CP Patients

Phase 3 Unknown

100 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT02602314 2022-01-20

SUSTRENIM

Phase 4 Unknown

450 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00481052 2022-01-18

CML0307

74 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00769327 2022-01-04

CML0408

129 enrolled